Nomenclature: D3 receptor

Family: Dopamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 400 3q13.3 DRD3 dopamine receptor D3 36
Mouse 7 446 16 B4 Drd3 dopamine receptor D3 101
Rat 7 446 11q21 Drd3 dopamine receptor D3 31
Previous and Unofficial Names
D3 receptor
D(3) dopamine receptor
dopamine D3 receptor
dopamine receptor D3
dopaminergic receptor D3
D3R
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
Orphanet Gene
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Structure of the human dopamine D3 receptor in complex with eticlopride
PDB Id:  3PBL
Ligand:  eticlopride
Resolution:  2.89Å
Species:  Human
References:  19
Natural/Endogenous Ligands
dopamine
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]7-OH-DPAT Hs Agonist 9.6 pKd 91
pKd 9.6 (Kd 2.7x10-10 M) [91]
[3H]PD128907 Hs Agonist 9.0 pKd 3
pKd 9.0 (Kd 9.9x10-10 M) [3]
lisuride Hs Partial agonist 9.6 pKi 76
pKi 9.6 [76]
cabergoline Hs Partial agonist 9.1 pKi 76
pKi 9.1 [76]
terguride Hs Partial agonist 9.0 pKi 76
pKi 9.0 [76]
roxindole Hs Partial agonist 8.9 pKi 76
pKi 8.9 [76]
pramipexole Hs Full agonist 8.4 – 8.7 pKi 72,94
pKi 8.4 – 8.7 [72,94]
(-)-N-porphynorapomorphine Hs Full agonist 8.4 – 8.7 pKi 32,94
pKi 8.4 – 8.7 [32,94]
rotigotine Hs Agonist 8.4 pKi 30
pKi 8.4 (Ki 4x10-9 M) [30]
pergolide Hs Partial agonist 8.3 pKi 76
pKi 8.3 [76]
7-OH-DPAT Hs Full agonist 7.1 – 8.4 pKi 13,21,32,65
pKi 7.1 – 8.4 [13,21,32,65]
ropinirole Hs Agonist 7.72 pKi 41
pKi 7.72 (Ki 1.9x10-8 M) [41]
7-trans-OH-PIPAT Hs Full agonist 7.7 pKi 21
pKi 7.7 [21]
apomorphine Rn Partial agonist 7.7 pKi 101
pKi 7.7 [101]
PD 128907 Hs Full agonist 7.6 – 7.7 pKi 88,94
pKi 7.6 – 7.7 [88,94]
bromocriptine Hs Partial agonist 7.1 – 8.2 pKi 32,76,94
pKi 7.1 – 8.2 [32,76,94]
quinpirole Rn Full agonist 7.3 – 7.8 pKi 13,101
pKi 7.3 – 7.8 [13,101]
quinelorane Hs Full agonist 7.2 – 7.4 pKi 77,100
pKi 7.2 – 7.4 [77,100]
quinpirole Hs Full agonist 6.4 – 8.0 pKi 13,72,77,84,100-101,110
pKi 6.4 – 8.0 [13,72,77,84,100-101,110]
bromocriptine Rn Full agonist 7.1 pKi 101
pKi 7.1 [101]
dopamine Hs Full agonist 6.4 – 7.3 pKi 13,32,94,101
pKi 6.4 – 7.3 [13,32,94,101]
apomorphine Hs Partial agonist 6.1 – 7.6 pKi 13,32,76,94,100
pKi 6.1 – 7.6 [13,32,76,94,100]
piribedil Hs Partial agonist 6.6 pKi 76
pKi 6.6 [76]
vilazodone Hs Agonist 7.15 pIC50 42
pIC50 7.15 (IC50 7.1x10-8 M) [42]
View species-specific agonist tables
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]nemonapride Hs Antagonist 10.3 pKd 66
pKd 10.3 [66]
[3H]spiperone Rn Antagonist 9.9 pKd 44,118
pKd 9.9 (Kd 1.25x10-10 M) [44,118]
S33084 Hs Antagonist 9.6 pKi 75
pKi 9.6 [75]
nafadotride Hs Antagonist 9.52 pKi 95
pKi 9.52 (3x10-10 M) [95]
nemonapride Hs Antagonist 9.2 – 9.3 pKi 65,107
pKi 9.2 – 9.3 [65,107]
PG01037 Hs Antagonist 9.2 pKi 40
pKi 9.2 [40]
spiperone Hs Antagonist 9.2 pKi 101
pKi 9.2 [101]
NGB 2904 Hs Antagonist 8.8 pKi 114
pKi 8.8 [114]
eticlopride Hs Antagonist 8.8 pKi 65,107
pKi 8.8 [65,107]
prochlorperazine Hs Antagonist 8.35 pKi 6
pKi 8.35 (Ki 4.45x10-9 M) [6]
zotepine Hs Antagonist 8.19 pKi 97
pKi 8.19 (Ki 6.4x10-9 M) [97]
cis-flupentixol Hs Antagonist 7.7 – 8.6 pKi 32
pKi 7.7 – 8.6 [32]
(+)-sulpiride Hs Antagonist 8.1 pKi 67
pKi 8.1 (Ki 7.99x10-9 M) [67]
SB 277011-A Hs Antagonist 8.0 pKi 89
pKi 8.0 [89]
raclopride Hs Antagonist 7.9 pKi 77
pKi 7.9 [77]
pimozide Hs Antagonist 7.0 – 8.6 pKi 32,100
pKi 7.0 – 8.6 [32,100]
haloperidol Hs Antagonist 7.5 – 8.0 pKi 32,100,109
pKi 7.5 – 8.0 [32,100,109]
raclopride Rn Antagonist 7.5 pKi 101
pKi 7.5 [101]
amisulpride Rn Antagonist 7.4 pKi 101
pKi 7.4 [101]
pimozide Rn Antagonist 7.4 pKi 101
pKi 7.4 [101]
(+)-butaclamol Rn Antagonist 7.3 – 7.5 pKi 13
pKi 7.3 – 7.5 [13]
domperidone Hs Antagonist 7.1 – 7.6 pKi 32,100
pKi 7.1 – 7.6 [32,100]
sulpiride Hs Antagonist 6.85 – 7.85 pKi 13
pKi 6.85 – 7.85 (Ki 1.42x10-7 – 1.4x10-8 M) [13]
chlorpromazine Hs Antagonist 7.2 – 7.5 pKi 32,100
pKi 7.2 – 7.5 [32,100]
(+)-butaclamol Hs Antagonist 6.7 – 8.0 pKi 32,88,107
pKi 6.7 – 8.0 [32,88,107]
(+)-UH232 Hs Antagonist 7.0 – 7.4 pKi 32,101
pKi 7.0 – 7.4 [32,101]
chlorpromazine Rn Antagonist 7.2 pKi 101
pKi 7.2 [101]
(-)-sulpiride Hs Antagonist 6.68 – 7.7 pKi 32,100,107
pKi 6.68 – 7.7 (Ki 2.07x10-7 – 2x10-8 M) [32,100,107]
(+)-UH232 Rn Antagonist 7.0 pKi 101
pKi 7.0 [101]
haloperidol Rn Antagonist 7.0 pKi 101
pKi 7.0 [101]
risperidone Hs Antagonist 7.0 pKi 77
pKi 7.0 [77]
domperidone Rn Antagonist 7.0 pKi 101
pKi 7.0 [101]
(+)-S-14297 Hs Antagonist 6.9 pKi 77
pKi 6.9 [77]
promazine Hs Antagonist 6.8 pKi 14
pKi 6.8 (Ki 1.59x10-7 M) [14]
(+)-sulpiride Rn Antagonist 6.4 pKi 101
pKi 6.4 [101]
(+)-AJ76 Hs Antagonist 5.9 – 6.2 pKi 77,100
pKi 5.9 – 6.2 [77,100]
(+)-AJ76 Rn Antagonist 6.0 pKi 101
pKi 6.0 [101]
clozapine Hs Antagonist 5.2 – 6.3 pKi 32,100
pKi 5.2 – 6.3 [32,100]
clozapine Rn Antagonist 5.7 pKi 101
pKi 5.7 [101]
trans flupenthixol Hs Antagonist 5.3 – 5.9 pKi 32
pKi 5.3 – 5.9 [32]
View species-specific antagonist tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
Potassium channel
References:  20,63,86-87,98
Tissue Distribution
Ventral striatum/nucleus accumbens > neostriatum, cerebral cortex, cerebellar cortex.
Species:  Human
Technique:  Autoradiography.
References:  43,54
Brain: nucleus accumbens and islands of Calleja.
Species:  Human
Technique:  in situ hybridization.
References:  56
Accumbens nucleus, islands of Calleja, bed nucleus of the stria terminalis, hippocampus, mammillary nuclei, substantia nigra.
Species:  Rat
Technique:  in situ hybridization.
References:  9
Brain: islands of Cajella, olafactory bulb, pituitary intermediate lobe > nucleus accumbens, molecular layer of the vestibulocerebellum, substantia nigra pars compacta.
Species:  Rat
Technique:  Autoradiography and in situ hybridization.
References:  7,34,55,60,64,83,90
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of adenylyl cyclase activity in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Inhibition of adenylyl cyclase.
References:  20
Measurement of extracellular acidification rates in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification rates.
References:  20
Measurement of extracellular acidification and D3 receptor membrane density in C6 glioma cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  C6 glioma cells.
Response measured:  Increase in extracellular acidification rate and receptor density.
References:  24
Measurement of c-fos activation and increased mitogenesis in neuroblastoma-glioma hybrid cells (NG108-15) transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in c-fos activation and mitogenesis.
References:  86
Measurement of cAMP accumulation in cultured Xenopus laevis melanophores transfected with the human D3 receptor.
Species:  Human
Tissue:  Cultured Xenopus laevis melanophores.
Response measured:  Inhibition of cAMP accumulation.
References:  87
Measurement of whole-cell potassium current in NG108-15 cells tranfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Reduction of peak whole-cell potassium current.
References:  63
Measurement of activation of GIRK1 in Xenopus oocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Activation of GIRK1.
References:  113
Measurement of mitogenesis in NG108-15 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in mitogenesis.
References:  94
Measurement of melanocyte aggregation in Xenopus melanocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus melanocytes.
Response measured:  Stimulation of melanocyte aggregation.
References:  12,88
Measurement of extracellular acidification in CHO cells transfected with the human D3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification.
References:  12
Measurement of activation of an 85 pS K+ channel known to be activated by dopamine and the "D2-like" agonist quinpirole.
Species:  Human
Tissue:  Freshly dissociated rat caudate-putamen neurons.
Response measured:  Activation of K+ channel.
References:  62
Measurement of dopamine release from a mesencephalic clonal cell line transfected with the D3 receptor.
Species:  Human
Tissue:  Neuronal mesencephalic MN9D cells.
Response measured:  Inhibition of dopamine release.
References:  108
Measurement of K+-stimulated tyrosine hydroxylase activity in D3 receptor-expressing MN9D cells.
Species:  Human
Tissue:  MN9D cells
Response measured:  Decrease in K+-stimulated tyrosine hydroxylase activity.
References:  81
Measurement of cAMP levels in HEK 293 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  69
Measurement of Cl- currents in Xenopus oocytes transfected with murine D3L and D3S receptors.
Species:  Mouse
Tissue:  Xenopus oocytes.
Response measured:  Stimulation of Cl- influx.
References:  99
Physiological Functions
Inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  27,88
Inhibition of locomotor activity.
Species:  Rat
Tissue:  In vivo.
References:  2,26,28,35,46,48,50,61,70,88,95,105-106,111-112
Modulation of motor activity.
Species:  Mouse
Tissue:  In vivo.
References:  103
Stimulation of yawning and hypothermia.
Species:  Rat
Tissue:  In vivo.
References:  2,27,48,53,73-74,77
Activation increases cell division.
Species:  Rat
Tissue:  CHO cells.
References:  20
Modulation of sniffing behaviour.
Species:  Rat
Tissue:  In vivo.
References:  26
Modulation of penile erection and ejaculatory behaviour.
Species:  Rat
Tissue:  In vivo.
References:  16,53
Modulation of self-administration of cocaine.
Species:  Rat
Tissue:  In vivo.
References:  15
Modulation of self-stimulation of the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  28
Modulation of reinforcing effects of cocaine and d-amphetamine.
Species:  Rat
Tissue:  In vivo.
References:  49
Stimulation of the D3 receptor decreases the rate of food-reinforced responding in a fixed-ratio operant paradigm.
Species:  Rat
Tissue:  In vivo.
References:  93
Stimulation of the D3 receptor produces an aversive effect in a conditioned place-preference paradigm.
Species:  Rat
Tissue:  In vivo.
References:  18
Hyperpolarization of neurons and inhibition of cell firing.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area of rat brain slices.
References:  10
A D3 agonist with relative selectivity for the dopamine D3 receptor, inhibits the firing of both A9 and A10 dopamine neurons and causes current-dependent inhibitions of spontaneously active or glutamate-driven caudate-putamen and nucleus accumbens neurons.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area dopamine neurons, and caudate-putamen and nucleus accumbens neurons in vivo.
References:  62
Systemic administration of a D3 receptor agonist decreases extracellular dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the nucleus accumbens and dopaminergic neuronal activity in the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  29
A D3 agonist inhibits substantia nigra pars compacta dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  52
A D3 agonist inhibits ventral tagmental area dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  59
Administration of a D3 agonist to freely moving rats decreases dialysate levels of dopamine in the nucleus accumbens.
Species:  Rat
Tissue:  In vivo.
References:  92
Application of a D3 receptor agonist reduces electrically-evoked dopamine release from the nucleus accumbens and striatum.
Species:  Rat
Tissue:  Nucleus accumbens and striatal slices.
References:  117
Modulation of dopamine synthesis.
Species:  Rat
Tissue:  In vivo.
References:  4,33,38,88
Physiological Consequences of Altering Gene Expression
D3 receptor knockout mice exhibit altered circadian pattern in spinal dopamine synthesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  22
D3 receptor knockout mice exhibit increased morphine-induced rewarding effects and potentiation of morphine-induced hyperlocomotion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  79
D3 receptor knockout mice exhibit higher basal levels of extracellular dopamine compared to the wild-type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  23,45
D3 receptor knockout mice display enhanced hyperactivity when compared to the wild-type, although these effects may be limited.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1,8,116
D3 receptor knockout mice display a transient increase in activity in a novel environment compared with wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  51,115
D3 receptor knockout mice exhibit increased behavioural sensitivity to combined injections of D1 and D2 class receptor agonists, cocaine and amphetamine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  116
D3 receptor knockout mice exhibit reduced anxiety.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  104
D3 receptor knockout mice exhibit renin-dependent hypertension.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  5
D3 receptor knockout mice exhibit increased gene expression in striatal neurons following acute administration of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  17
D3 receptor knockout mice exhibit aggravation of the development of physical dependence on ethanol.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  80
D3 receptor knockout mice display similar effects (reward/intake) of ethanol as wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11
D3 receptor knockout mice exhibit increased D1/D2 receptor-mediated intracellular signalling.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  78
D3 receptor knockout mice exhibit increased adiposity induced by a high-fat diet.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  71
D3 receptor knockout mice exhibit neuroadaptive changes which support the role of D3 receptors as autoreceptors.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  58
D3 receptor knockout mice display increased susceptibility to cocaine addition
Species:  Mouse
Tissue: 
Technique:  Gene knockout
References:  102
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
+|Cm|Drd3tm1Stl Cm/+,Drd3tm1Stl/Drd3tm1Stl
involves: 101/H * 129S2/SvPas * C3H/HeH * C3H/HeSn * C57BL/6J
MGI:88424  MGI:94925  MP:0009748 abnormal behavioral response to addictive substance PMID: 19840852 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0001454 abnormal cued conditioning behavior PMID: 9354330 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005449 abnormal food intake PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2+|Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2+,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0000676 abnormal water content PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 16525059 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd
MGI:94925  MP:0005643 decreased dopamine level PMID: 12044470 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001505 hunched posture PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0001399 hyperactivity PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005669 increased circulating leptin level PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0003867 increased defecation PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0003911 increased drinking behavior PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0003909 increased eating behavior PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0001415 increased exploration in new environment PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005458 increased percent body fat PMID: 15084447 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd
MGI:94925  MP:0001409 increased stereotypic behavior PMID: 12044470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005455 increased susceptibility to weight gain PMID: 15084447 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0010024 increased total body fat amount PMID: 15084447 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0002082 postnatal lethality PMID: 10391470 
Clinically-Relevant Mutations and Pathophysiology
Disease:  Hereditary essential tremor, 1
OMIM:  190300
Orphanet:  862
References: 
Mutations not determined
Biologically Significant Variants
Type:  Point mutation.
Species:  Human
Description:  The BalI restriction fragment length polymorphism (corresponding to a point mutation in the 1st exon and resulting in a serine-to-glycine substitution in the N-terminal extracellular domain of the receptor) has been associated with schizophrenia.
References:  25,47,68
Type:  Point mutation.
Species:  Human
Description:  The BalI polymorphism has been associated with bipolar disorder.
References:  82
General Comments
Alternative splicing leads to a 425aa isoform in mouse[31] and several shorter presumably inactive isoforms in rat[37] and human[96]. Two polymorphic variants [Ser9] and [Gly9] in human[57]. The organization of the coding sequence of the human gene has been established[39]. Anti-psychotic drugs display closely similar or slightly lower antagonist affinity at D3 compared to D2 receptors. S(+)14297, initially reported as a D3 receptor antagonist[77] displays full agonist activity in two functional assays[85].
Available Assays
DiscoveRx PathHunter® CHO-K1 DRD3 β-Arrestin Cell Line (Cat no. 93-0591C2)
PathHunter® eXpress DRD3 U2OS β-Arrestin GPCR Assay (Cat no. 93-0591E3CP0M)
PathHunter® U2OS DRD3 β-Arrestin Cell Line (Cat no. 93-0591C3)
more info

REFERENCES

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda E B, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S. (1996) A targeted mutation of the D3 receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A.93: 1945-1949. [PMID:8700864]

2. Ahlenius S, Salmi P. (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol260: 177-181. [PMID:7988642]

3. Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikström H, Heffner TG, Wise LD, Pugsley TA. (1995) Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci.57 (15): 1401-10. [PMID:7674830]

4. Aretha CW, Sinha A, Galloway MP. (1995) Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther274: 609-613. [PMID:7636720]

5. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA Eisner G, Jose PA. (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J. Clin. Invest.102: 493-498. [PMID:9691085]

6. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicoligy Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

7. Booze RM, Wallace DR. (1995) Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse19: 1-13. [PMID:7709338]

8. Boulay D, Depoortere R, Rostene W, Perrault G, Sanger DJ. (1999) Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology38: 555-565. [PMID:10221759]

9. Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C. (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with D2 receptor mRNA. Brain Res.564: 203-219. [PMID:1839781]

10. Bowery B, Rothwell LA, Seabrook GR. (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol112: 873-880. [PMID:7921615]

11. Boyce-Rustay JM, Risinger FO. (2003) Dopamine D3 receptor knockout mice and the motivational effects of ethanol. Pharmacol Biochem Behav75: 373-379. [PMID:12873629]

12. Boyfield I, Winn F, Coldwell M. (1996) Comparison of agonist potencies at human dopamine D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem Soc Trans24: 57S-57S. [PMID:8674731]

13. Burris KD, Pacheco MA, Filtz TM, Kung MP, Kung HF, Molinoff PB. (1995) Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology12: 335-345. [PMID:7576010]

14. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U et al.. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther.315 (3): 1278-87. [PMID:16135699]

15. Caine SB, Koob GF. (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science260: 1814-1816. [PMID:8099761]

16. Carlsson A, Lindqvist M, Magnusson M. (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature180: 1200-. [PMID:13483658]

17. Carta AR, Gerfen CR, Steiner H. (2000) Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport11: 2395-2399. [PMID:10943692]

18. Chaperon F, Thiébot MH. (1996) Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol7: 105-109. [PMID:11224401]

19. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V et al.. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science330 (6007): 1091-5. [PMID:21097933]

20. Chio CL, Lajiness ME, Huff RM. (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol45: 51-60. [PMID:8302280]

21. Chumpradit S, Kung MP, Vessotskie J, Foulon C, Mu M, Kung HF. (1994) Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem37: 4245-4250. [PMID:7990123]

22. Clemens S, Sawchuk MA, Hochman S. (2005) Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D3 receptor knockout mice. Neuroscience133: 353-357. [PMID:15878801]

23. Cooper DC, Loeltzow TE, Xu M, Tonegawa S, White FJ, Wolf ME. (1996) Regulations of dopamine release and synthesis in dopamine D3R receptor knockout mice. (Abstract) Soc. Neurosci. Abst.22: 1319-.

24. Cox BA, Rosser MP, Kozlowski MR, Duwe KM, Neve RL, Neve KA. (1995) Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse21: 1-9. [PMID:8525456]

25. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet29: 858-860. [PMID:1362221]

26. Daly SA, Waddington JL. (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology32: 509-510. [PMID:8321432]

27. Damsma G, Bottema T, Westerink BH, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikström H. (1993) Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol249: R9-10. [PMID:8287911]

28. Depoortere R, Perrault G, Sanger DJ. (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl)124: 231-240. [PMID:8740044]

29. Devoto P, Collu M, Muntoni AL, Pistis M, Serra G, Gessa GL, Diana M. (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse20: 153-155. [PMID:7570345]

30. Dijkstra D, Rodenhuis N, Vermeulen ES, Pugsley TA, Wise LD, Wikström HV. (2002) Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. J. Med. Chem.45 (14): 3022-31. [PMID:12086487]

31. Fishburn C, Bellili D, David C, Carmon S, Fuchs S. (1993) A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J. Biol. Chem.268: 5872-5878. [PMID:8449953]

32. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther268: 417-426. [PMID:8301582]

33. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol308: 261-269. [PMID:8858296]

34. Gehlert DR, Gackenheimer SL, Seeman P, Schaus J. (1992) Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol211: 189-194. [PMID:1351846]

35. Gilbert DB, Cooper SJ. (1995) 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects?. Pharmacol Biochem Behav52: 275-280. [PMID:8577791]

36. Giros B, Martres M-P, Sokoloff P, Schwartz J-C. (1990) cDNA cloning of the human dopaminergic D3 receptor and chromosome identification. C. R. Acad. Sci. III311: 501-508. [PMID:2129115]

37. Giros B, Martres MP, Pilon C, Sokoloff P, Schwartz JC. (1991) Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochem. Biophys. Res. Commun.176: 1584-1592. [PMID:2039532]

38. Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther275: 899-913. [PMID:7473181]

39. Griffon N, Crocq MA, Pilon C, Martres MP, Mayerova A, Uyanik G, Burgert E, Duval F, Macher JP, Javoy-Agid F, Tamminga CA, Schwartz JC, Sokoloff P. (1996) Dopamine D3 receptor gene: organization, transcript variants and polymorphism associated with schizophrenia. Am. J. Med. Genet.67: 58-70. [PMID:8678117]

40. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH. (2007) Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem.50 (17): 4135-46. [PMID:17672446]

41. Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJ et al.. (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. J. Med. Chem.40 (5): 639-46. [PMID:9057850]

42. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem.47 (19): 4684-92. [PMID:15341484]

43. Herroelen L, De Backer JP, Wilczak N, Flamez A, Vauquelin G, De Keyser J. (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res648: 222-228. [PMID:7922537]

44. Hoare SR, Coldwell MC, Armstrong D, Strange PG. (2000) Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br. J. Pharmacol.130 (5): 1045-59. [PMID:10882389]

45. Joseph JD, Wang YM, Miles PR, Budygin EA, Picetti R, Gainetdinov RR, Caron MG, Wightman RM. (2002) Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience112: 39-49. [PMID:12044470]

46. Kagaya T, Yonaga M, Furuya Y, Hashimoto T, Kuroki J, Nishizawa Y. (1996) Dopamine D3 agonists disrupt social behavior in rats. Brain Res721: 229-232. [PMID:8793104]

47. Kennedy JL, Billett EA, Macciardi FM, Verga M, Parsons TJ, Meltzer HY, Lieberman J, Buchanan JA. (1995) Association study of dopamine D3 receptor gene and schizophrenia. Am J Med Genet60: 558-562. [PMID:8825896]

48. Khroyan TV, Baker DA, Neisewander JL. (1995) Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl)122: 351-357. [PMID:8657832]

49. Kling-Petersen T, Ljung E, Svensson K. (1994) The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm. Pharmacol Biochem Behav49: 345-351. [PMID:7824548]

50. Kling-Petersen T, Ljung E, Svensson K. (1995) Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect102: 209-220. [PMID:8788069]

51. Koeltzow T, Cooper DC, Hu X-T, Xu M, Tonegawa S, White FJ. (1995) In vivo effects of dopaminergic ligands on dopamine D3 receptor deficient mice. (Abstract) Soc. Neurosci. Abst.21: 364-.

52. Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. (1995) Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol277: 209-214. [PMID:7493610]

53. Kurashima M, Yamada K, Nagashima M, Shirakawa K, Furukawa T. (1995) Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav52: 503-508. [PMID:8545466]

54. Lahti RA, Roberts RC, Tamminga CA. (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport6: 2505-2512. [PMID:8741751]

55. Landwehrmeyer B, Mengod G, Palacios JM. (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci5: 145-153. [PMID:8261096]

56. Landwehrmeyer B, Mengod G, Palacios JM. (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res18: 187-192. [PMID:8097550]

57. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jonsson E, Sedvall G, Schwartz JC. (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genet.2: 249-256.

58. Le Foll B, Diaz J, Sokoloff P. (2005) Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci76: 1281-1296. [PMID:15642598]

59. Lejeune F, Millan MJ. (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol275: R7-R9. [PMID:7768288]

60. Levant B, Grigoriadis DE, DeSouza EB. (1992) Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J Pharmacol Exp Ther262: 929-935. [PMID:1356154]

61. Levant B, Vansell NR. (1997) In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology17: 67-71. [PMID:9252981]

62. Liu JC, Cox RF, Greif GJ, Freedman JE, Waszczak BL. (1994) The putative dopamine D3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol264: 269-278. [PMID:7698165]

63. Liu LX, Monsma FJ, Sibley DR, Chiodo LA. (1996) D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse24: 156-164. [PMID:8890457]

64. Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A89: 8155-8159. [PMID:1518841]

65. MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O'Malley KL. (1994) Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol266: 79-85. [PMID:7907989]

66. Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU. (2003) Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem87: 631-641. [PMID:14535946]

67. Malmberg A, Jackson DM, Eriksson A, Mohell N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol43: 749-754. [PMID:8099194]

68. Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ. (1994) Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet54: 21-26. [PMID:7909989]

69. McAllister G, Knowles MR, Ward-Booth SM, Sinclair HA, Patel S, Marwood R, Emms F, Patel S, Smith A, Seabrook GR. (1995) Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells. J Recept Signal Transduct Res15: 267-281. [PMID:8903944]

70. McElroy J, Zeller KL, Amy KA, Ward KA, Cawley JF, Mazzola AL, Keim W, Rohrbach K. (1993) In vivo agonist properties of 7-hydroxy-N,N-Di-N-propyl-2-aminotetralin, a dopamine D3-selective receptor ligand. Drug Development Research30: 257-259.

71. McQuade JA, Benoit SC, Xu M, Woods SC, Seeley RJ. (2004) High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene. Behav Brain Res151: 313-319. [PMID:15084447]

72. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol290: 29-36. [PMID:7664822]

73. Millan MJ, Audinot V, Melon C, Newman-Tancredi A. (1995) Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. Eur J Pharmacol280: 225-229. [PMID:7589191]

74. Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL. (1994) S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol260: R3-R5. [PMID:7988633]

75. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther293: 1048-1062. [PMID:10869410]

76. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther303: 791-804. [PMID:12388666]

77. Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther275: 885-898. [PMID:7473180]

78. Mizuo K, Narita M, Miyatake M, Suzuki T. (2004) Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor. Neurosci Lett358: 13-16. [PMID:15016423]

79. Narita M, Mizuo K, Mizoguchi H, Sakata M, Narita M, Tseng LF, Suzuki T. (2003) Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion. J Neurosci23: 1006-1012. [PMID:12574430]

80. Narita M, Soma M, Tamaki H, Narita M, Suzuki T. (2002) Intensification of the development of ethanol dependence in mice lacking dopamine D(3) receptor. Neurosci Lett324: 129-132. [PMID:11988344]

81. O'hara CM, Uhland-Smith A, O'Malley KL, Todd RD. (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther277: 186-192. [PMID:8613917]

82. Parsian A, Chakraverty S, Todd RD. (1995) Possible association between the dopamine D3 receptor gene and bipolar affective disorder. Am J Med Genet60: 234-237. [PMID:7573178]

83. Parsons B, Stanley M, Javitch J. (1993) Differential visualization of dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol234: 269-272. [PMID:8097723]

84. Patel S, Patel S, Marwood R, Emms F, Marston D, Leeson PD, Curtis NR, Kulagowski JJ, Freedman SB. (1996) Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol50: 1658-1664. [PMID:8967990]

85. Perachon S, Betancur C, Pilon C, Rostene W, Schwartz JC, Sokoloff P. (2000) Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport11: 221-225. [PMID:10683862]

86. Pilon C, Lévesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC, Sokoloff P. (1994) Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol268: 129-139. [PMID:7957635]

87. Potenza MN, Graminski GF, Schmauss C, Lerner MR. (1994) Functional expression and characterization of human D2 and D3 dopamine receptors. J Neurosci14: 1463-1476. [PMID:7907363]

88. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther275: 1355-1366. [PMID:8531103]

89. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther294: 1154-1165. [PMID:10945872]

90. Ricci A, Vega JA, Mammola CL, Amenta F. (1995) Localisation of dopamine D3 receptor in the rat cerebellar cortex: a light microscope autoradiographic study. Neurosci Lett190: 163-166. [PMID:7637884]

91. Ricci A, Veglio F, Amenta F. (1995) Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT. J. Neuroimmunol.58 (2): 139-44. [PMID:7759603]

92. Rivet JM, Audinot V, Gobert A, Peglion JL, Millan MJ. (1994) Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol265: 175-177. [PMID:7875234]

93. Sanger DJ, Depoortere R, Perrault G. (1996) Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behav Pharmacol7: 477-482. [PMID:11224444]

94. Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, Sokoloff P. (1995) A functional test identifies dopamine agonists selective for D3versus D2receptors. Neuroreport6: 329-332. [PMID:7756621]

95. Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A et al.. (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther.275: 1239-1246. [PMID:8531087]

96. Schmauss C, Haroutunian V, Davis KL, Davidson M. (1993) Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. U.S.A.90: 8942-8946. [PMID:8415635]

97. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl)124: 57-73. [PMID:8935801]

98. Seabrook GR, Patel S, Marwood R, Emms F, Knowles MR, Freedman SB, McAllister G. (1992) Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells. FEBS Lett312: 123-126. [PMID:1330688]

99. Skaaning Jensen B, Levavi-Sivan B, Fishburn CS, Fuchs S. (1997) Functional expression of the murine D2, D3, and D4 dopamine receptors in Xenopus laevis oocytes. FEBS Lett420: 191-195. [PMID:9459308]

100. Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres M-P, Giros B, Schwartz J-C. (1992) Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line : comparison with D2 receptor. Eur. J. Pharmacol.225: 331-337. [PMID:1354163]

101. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature347: 146-151. [PMID:1975644]

102. Song R, Zhang HY, Li X, Bi GH, Gardner EL, Xi ZX. (2012) Increased vulnerability to cocaine in mice lacking dopamine D3 receptors. Proc. Natl. Acad. Sci. U.S.A.109 (43): 17675-80. [PMID:23045656]

103. Starr MS, Starr BS. (1995) Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors. Eur J Pharmacol277: 151-158. [PMID:7493603]

104. Steiner H, Fuchs S, Accili D. (1997) D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav63: 137-141. [PMID:9402626]

105. Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N. (1994) Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol263: 235-243. [PMID:7843260]

106. Svensson K, Carlsson A, Waters N. (1994) Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect95: 71-74. [PMID:7857588]

107. Tang L, Todd RD, Heller A, O'Malley KL. (1994) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther268: 495-502. [PMID:8301592]

108. Tang L, Todd RD, O'Malley KL. (1994) Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther270: 475-479. [PMID:8071839]

109. Tice MA, Hashemi T, Taylor LA, Duffy RA, McQuade RD. (1994) Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol. Biochem. Behav.49 (3): 567-71. [PMID:7862709]

110. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature350: 610-614. [PMID:1840645]

111. Waters N, Löfberg L, Haadsma-Svensson S, Svensson K, Sonesson C, Carlsson A. (1994) Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm Gen Sect98: 39-55. [PMID:7710738]

112. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. (1993) The dopamine D3 receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. Gen. Sect.94: 11-19. [PMID:8129881]

113. Werner P, Hussy N, Buell G, Jones KA, North RA. (1996) D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol Pharmacol49: 656-661. [PMID:8609893]

114. Xi ZX, Gardner EL. (2007) Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev13 (2): 240-59. [PMID:17627675]

115. Xu M, Caine SB, Cooper DC, Gold LH, Graybiel AM, Hu XT, Loeltzow T, Koob GF, Moratalla R, White FJ, Tonegawa S. (1995) Analysis of dopamine D3 and D1 receptor mutant mice. (Abstract) Soc. Neurosci. Abst.21: 363-.

116. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S. (1997) Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron79: 837-848. [PMID:9354330]

117. Yamada S, Yokoo H, Nishi S. (1994) Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res648: 176-179. [PMID:7922522]

118. Zhen J, Antonio T, Dutta AK, Reith ME. (2010) Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. J. Neurosci. Methods188 (1): 32-8. [PMID:20122961]

To cite this database page, please use the following:

Arvid Carlsson, Marc G. Caron, Olivier Civelli, John W. Kebabian, Saloman Z. Langer, Bernard Scatton, Jean-Charles Schwartz, Goran Sedvall, Philip Seeman, Pierre Sokoloff, Pierre F. Spano, Hubert H. M. Van Tol.
Dopamine receptors: D3 receptor. Last modified on 11/06/2014. Accessed on 29/07/2014. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=216.

Contact us | Print | Back to top | Help
Copyright © 2014 IUPHAR